A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo
Authors:
- Giuseppina MilanoGMGiuseppina Milano
- Sandrine MorelSandrine Morel
- Christophe BonnyCBChristophe Bonny
- Michele SamajaMichele Samaja
- Ludwig K. von SegesserLSLudwig K. von Segesser
- Pascal NicodPNPascal Nicod
- Giuseppe VassalliGVGiuseppe Vassalli
- 1 April 2007
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 292 (4) , H1828-H1835
Abstract
The c-Jun NH2-terminal kinase (JNK) pathway of the mitogen-activated protein kinase (MAPK) signaling cascade regulates cell function and survival after stress stimulation. Equally robust studies reported dichotomous results suggesting both protective and detrimental effects of JNK during myocardial ischemia-reperfusion (I/R). The lack of a highly specific JNK inhibitor contributed to this controversy. We recently developed a cell-penetrating, protease-resistant peptide inhibitor of JNK, d-JNKI-1. Here we report on the effects of d-JNKI-1 in myocardial I/R. d-JNKI-1 was tested in isolated-perfused adult rat hearts. Increased activation of JNK, p38-MAPK, and extracellular signal-regulated kinase-1/2 (ERK1/2), as assessed by kinase assays and Western blotting, occurred during I/R. d-JNKI-1 delivered before onset of ischemia prevented the increase in JNK activity while not affecting ERK1/2 and p38-MAPK activation. JNK inhibition reduced ischemic injury, as manifested by increased time to contracture ( P < 0.05) and decreased left ventricular end-diastolic pressure during ischemia ( P < 0.01), and enhanced posthypoxic recovery of systolic and diastolic function ( P < 0.01). d-JNKI-1 reduced mitochondrial cytochrome- c release, caspase-3 activation, and the number of apoptotic cells determined by terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling ( P < 0.05), indicating suppression of the mitochondrial machinery of apoptosis. d-JNKI-1 delivered at the time of reperfusion did not improve functional recovery but still prevented apoptosis. In vivo, d-JNKI-1 reduced infarct size after coronary artery occlusion and reperfusion by ∼50% ( P < 0.01). In conclusion, d-JNKI-1 is an important compound that can be used in preclinical models to investigate the role of JNK signaling in vivo. Inhibition of JNK during I/R is cardioprotective in anesthetized rats in vivo.Keywords
This publication has 31 references indexed in Scilit:
- Switch from Caspase-dependent to Caspase-independent Death during Heart DevelopmentJournal of Biological Chemistry, 2006
- A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemiaNature Medicine, 2003
- Characterization of apoptosis signal transduction pathways in HL‐5 cardiomyocytes exposed to ischemia/reperfusion oxidative stress modelJournal of Cellular Physiology, 2003
- Direct Activation of Mitochondrial Apoptosis Machinery by c-Jun N-terminal Kinase in Adult Cardiac MyocytesJournal of Biological Chemistry, 2002
- Identification of the Critical Features of a Small Peptide Inhibitor of JNK ActivityJournal of Biological Chemistry, 2002
- Cytoprotection by Jun Kinase During Nitric Oxide–Induced Cardiac Myocyte ApoptosisCirculation Research, 2001
- Cell-Permeable Peptide Inhibitors of JNKDiabetes, 2001
- Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcuminOncogene, 1998
- The p38‐MAPK inhibitor, SB203580, inhibits cardiac stress‐activated protein kinases/c‐Jun N‐terminal kinases (SAPKs/JNKs)FEBS Letters, 1998
- Preconditioning During IschemiaCardiology in Review, 1995